Neoadjuvant Trastuzumab: Marked Benefit in HER2-Positive Inflammatory Breast Cancer

Jose Baselga

Gordon McVie
JOSE BASELGA, Vall d’Hebron University Hospital, Barcelona
COMMENT: GORDON MCVIE, European Institute of Oncology, Milan
Neoadjuvant trastuzumab for patients with HER2-positive